193 related articles for article (PubMed ID: 29761241)
1. Glucocorticoids in the treatment of patients with primary focal segmental glomerulosclerosis and moderate proteinuria.
Huang J; Lin L; Xie J; Li X; Shen P; Pan X; Ren H; Chen N
Clin Exp Nephrol; 2018 Dec; 22(6):1315-1323. PubMed ID: 29761241
[TBL] [Abstract][Full Text] [Related]
2. Effects of angiotensin-converting enzyme inhibitor and steroid therapy on proteinuria in FSGS: a retrospective study in a single clinic.
Stiles KP; Abbott KC; Welch PG; Yuan CM
Clin Nephrol; 2001 Aug; 56(2):89-95. PubMed ID: 11522100
[TBL] [Abstract][Full Text] [Related]
3. Primary FSGS in Nephrotic Adults: Clinical Profile, Response to Immunosuppression and Outcome.
Bagchi S; Agarwal S; Kalaivani M; Bhowmik D; Singh G; Mahajan S; Dinda A
Nephron; 2016; 132(2):81-5. PubMed ID: 26799973
[TBL] [Abstract][Full Text] [Related]
4. Treatment and prognosis of primary focal segmental glomerulosclerosis.
Ren H; Shen P; Li X; Pan X; Zhang Q; Feng X; Zhang W; Chen N
Contrib Nephrol; 2013; 181():109-18. PubMed ID: 23689573
[TBL] [Abstract][Full Text] [Related]
5. Effects of spironolactone in combination with angiotensin-converting enzyme inhibitors or Angiotensin receptor blockers in patients with proteinuria.
Kim HY; Bae EH; Ma SK; Kim SW
Kidney Blood Press Res; 2014; 39(6):573-80. PubMed ID: 25531940
[TBL] [Abstract][Full Text] [Related]
6. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
Esnault VL; Ekhlas A; Nguyen JM; Moranne O
Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with lamivudine and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for hepatitis B virus-associated glomerulonephritis with mild to moderate proteinuria: a clinical review of 38 cases.
Sun LJ; Shan JP; Cui RL; Yuan WJ; Jiang GR
Int Urol Nephrol; 2017 Jun; 49(6):1049-1056. PubMed ID: 28283858
[TBL] [Abstract][Full Text] [Related]
8. Differential risk of remission and ESRD in childhood FSGS.
Gipson DS; Chin H; Presler TP; Jennette C; Ferris ME; Massengill S; Gibson K; Thomas DB
Pediatr Nephrol; 2006 Mar; 21(3):344-9. PubMed ID: 16395603
[TBL] [Abstract][Full Text] [Related]
9. Renal Survival in Patients with Collapsing Compared with Not Otherwise Specified FSGS.
Laurin LP; Gasim AM; Derebail VK; McGregor JG; Kidd JM; Hogan SL; Poulton CJ; Detwiler RK; Jennette JC; Falk RJ; Nachman PH
Clin J Am Soc Nephrol; 2016 Oct; 11(10):1752-1759. PubMed ID: 27445167
[TBL] [Abstract][Full Text] [Related]
10. Proteinuria Reduction and Kidney Survival in Focal Segmental Glomerulosclerosis.
Troost JP; Trachtman H; Spino C; Kaskel FJ; Friedman A; Moxey-Mims MM; Fine RN; Gassman JJ; Kopp JB; Walsh L; Wang R; Gipson DS
Am J Kidney Dis; 2021 Feb; 77(2):216-225. PubMed ID: 32791086
[TBL] [Abstract][Full Text] [Related]
11. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN; Alpers CE; Barratt J; Bieler S; Canetta P; Chae DW; Coppock G; Diva U; Gesualdo L; Heerspink HJL; Inrig JK; Kirsztajn GM; Kohan D; Komers R; Kooienga LA; Lieberman K; Mercer A; Noronha IL; Perkovic V; Radhakrishnan J; Rote W; Rovin B; Tesar V; Trimarchi H; Tumlin J; Wong MG; Trachtman H;
N Engl J Med; 2023 Dec; 389(26):2436-2445. PubMed ID: 37921461
[TBL] [Abstract][Full Text] [Related]
12. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade.
Ferrari P; Marti HP; Pfister M; Frey FJ
J Hypertens; 2002 Jan; 20(1):125-30. PubMed ID: 11791035
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis.
Heering P; Braun N; Müllejans R; Ivens K; Zäuner I; Fünfstück R; Keller F; Krämer BK; Schollmeyer P; Risler T; Grabensee B;
Am J Kidney Dis; 2004 Jan; 43(1):10-8. PubMed ID: 14712422
[TBL] [Abstract][Full Text] [Related]
14. An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis.
Troost JP; Trachtman H; Nachman PH; Kretzler M; Spino C; Komers R; Tuller S; Perumal K; Massengill SF; Kamil ES; Oh G; Selewski DT; Gipson P; Gipson DS
Clin J Am Soc Nephrol; 2018 Mar; 13(3):414-421. PubMed ID: 29167190
[TBL] [Abstract][Full Text] [Related]
15. Focal segmental glomerulosclerosis complicating solitary kidney.
Oshiro Y; Umena S; Noda M
Clin Exp Nephrol; 2009 Feb; 13(1):81-4. PubMed ID: 18688570
[TBL] [Abstract][Full Text] [Related]
16. The treatment of idiopathic focal segmental glomerulosclerosis in adults.
Hogan J; Radhakrishnan J
Adv Chronic Kidney Dis; 2014 Sep; 21(5):434-41. PubMed ID: 25168833
[TBL] [Abstract][Full Text] [Related]
17. Proteinuria as a risk marker for the progression of chronic kidney disease in patients on predialysis care and the role of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment.
de Goeij MC; Liem M; de Jager DJ; Voormolen N; Sijpkens YW; Rotmans JI; Boeschoten EW; Dekker FW; Grootendorst DC; Halbesma N;
Nephron Clin Pract; 2012; 121(1-2):c73-82. PubMed ID: 23128440
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatment.
Usta M; Ersoy A; Dilek K; Ozdemir B; Yavuz M; Güllülü M; Yurtkuran M
J Intern Med; 2003 Mar; 253(3):329-34. PubMed ID: 12603500
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial.
Esteghamati A; Noshad S; Jarrah S; Mousavizadeh M; Khoee SH; Nakhjavani M
Nephrol Dial Transplant; 2013 Nov; 28(11):2823-33. PubMed ID: 24009294
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors.
Seeman T; Pohl M; Misselwitz J; John U
Kidney Blood Press Res; 2009; 32(6):440-4. PubMed ID: 20016211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
